Allogene Therapeutics, Inc.

NasdaqGS:ALLO Lagerbericht

Marktkapitalisierung: US$490.6m

Allogene Therapeutics Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

David Chang

Geschäftsführender

US$14.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts5.1%
Amtszeit als Geschäftsführer6yrs
Eigentum des Geschäftsführers3.7%
Durchschnittliche Amtszeit des Managements1.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.2yrs

Jüngste Management Updates

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Recent updates

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Jun 12

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Apr 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Jun 09
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Feb 22
We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Oct 27
Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate

Oct 06

An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Sep 22
An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A

Sep 13

Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M

Aug 09

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Jul 14
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Allogene Therapeutics: Multibagger Potential, But Terribly Risky

Jun 24

Allogene: Leading The Allogeneic CAR-T Space, Again

Apr 01

Allogene: Lifting Of The Clinical Hold Will Be A Major Binary

Jan 12

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Chang im Vergleich zu den Einnahmen von Allogene Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-US$292m

Dec 31 2023US$14mUS$724k

-US$327m

Sep 30 2023n/an/a

-US$342m

Jun 30 2023n/an/a

-US$364m

Mar 31 2023n/an/a

-US$361m

Dec 31 2022US$15mUS$724k

-US$340m

Sep 30 2022n/an/a

-US$313m

Jun 30 2022n/an/a

-US$308m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$10mUS$695k

-US$182m

Sep 30 2021n/an/a

-US$251m

Jun 30 2021n/an/a

-US$239m

Mar 31 2021n/an/a

-US$229m

Dec 31 2020US$8mUS$675k

-US$316m

Sep 30 2020n/an/a

-US$243m

Jun 30 2020n/an/a

-US$227m

Mar 31 2020n/an/a

-US$207m

Dec 31 2019US$11mUS$600k

-US$185m

Sep 30 2019n/an/a

-US$154m

Jun 30 2019n/an/a

-US$147m

Mar 31 2019n/an/a

-US$240m

Dec 31 2018US$13mUS$362k

-US$212m

Geschäftsführer

David Chang (64 yo)

6yrs

Amtszeit

US$14,061,848

Vergütung

Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc since June 2018. He served as Chief Medical Officer and Executive Vice President of Rese...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Arie Belldegrun
Co-Founder & Executive Chairman6.6yrsUS$9.36m2.94%
$ 14.4m
David Chang
Co-Founder6yrsUS$14.06m3.7%
$ 18.1m
Joshua Kazam
Co-Founder & Directorno dataUS$684.49k0.15%
$ 712.2k
Timothy Moore
Executive VP & Chief Technical Officer1.2yrsUS$5.80m0.13%
$ 623.9k
Zachary Roberts
Executive VP of Research & Development and Chief Medical Officer1.4yrsUS$8.13m0.018%
$ 90.0k
Geoffrey Parker
Executive VP & CFOless than a yearkeine Daten0.17%
$ 810.8k
Annie Yoshiyama
Senior VPno datakeine Datenkeine Daten
Earl Douglas
Senior VPless than a yearkeine Daten0%
$ 0
Susan Lundeen
Chief People Officer2.1yrskeine Datenkeine Daten
Christine Cassiano
Executive VP1.4yrskeine Datenkeine Daten
Yinlin Chen
Senior Vice President of Financeno datakeine Daten0.043%
$ 208.9k
David Tanen
Secretaryno datakeine Datenkeine Daten

1.3yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Arie Belldegrun
Co-Founder & Executive Chairman6.6yrsUS$9.36m2.94%
$ 14.4m
David Chang
Co-Founder6yrsUS$14.06m3.7%
$ 18.1m
Joshua Kazam
Co-Founder & Director6.6yrsUS$684.49k0.15%
$ 712.2k
David Bonderman
Lead Independent Director6.2yrskeine Datenkeine Daten
Franz Humer
Independent Director6.2yrsUS$585.00k0.15%
$ 744.3k
Owen Witte
Independent Director6.2yrsUS$510.00k0.12%
$ 600.5k
Todd Sisitsky
Independent Director6.2yrskeine Datenkeine Daten
Deborah Messemer
Independent Director5.8yrsUS$495.00k0.089%
$ 435.7k
Matthew Porteus
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Donald Kohn
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Antonius Schumacher
Chairman of Scientific Advisory Boardno datakeine Datenkeine Daten
John DeYoung
Independent Director6.2yrskeine Datenkeine Daten

6.2yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter